Canopy Growth Discloses Non-Reliance on Past Financials, Expects Restatement and Material Weakness
CGC sits 22% above its 52-week low of $0.844.
Summary
Canopy Growth announced it cannot rely on its past two years of financial statements due to accounting errors, will restate them, and expects to report a material weakness in internal controls.
Key Events · Legal and Risk Events · CGC
-
Non-Reliance on Financial Statements
The company's audited consolidated financial statements for fiscal years ended March 31, 2024, and March 31, 2025, and several unaudited interim periods, should no longer be relied upon.
-
Reason for Restatement
The non-reliance is due to non-cash technical errors in accounting related to the classification of certain share-settled warrants as equity instead of liabilities.
-
Material Weakness in Internal Controls
Management expects to report a material weakness in the company's internal control over financial reporting.
-
Restatement Plan
The company intends to restate the affected financial statements in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, expected to be filed on June 15, 2026.
Analysis · CGC · Life Sciences
Canopy Growth announced that its financial statements for fiscal years 2024 and 2025, along with several interim periods, can no longer be relied upon due to technical accounting errors related to the classification of share-settled warrants. The company expects to report a material weakness in internal controls and will restate these financials in its upcoming 10-K. While the company states these are non-cash adjustments not impacting revenue, cash flows, liquidity, or debt covenants, the inability to rely on past financial reports and the disclosure of a material weakness are significant concerns for investors regarding financial transparency and control. The voluntary application for a management cease trade order further underscores the seriousness of the situation.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGC was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $470.2M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.